Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning.

acetylcholinesterase reactivation blood-brain barrier cationic liposome imidazolium surfactant targeted drug delivery

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
15 Sep 2022
Historique:
received: 29 07 2022
revised: 31 08 2022
accepted: 09 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

One of the main problems in the treatment of poisoning with organophosphorus (OPs) inhibitors of acetylcholinesterase (AChE) is low ability of existing reactivators of AChE that are used as antidotes to cross the blood-brain barrier (BBB). In this work, modified cationic liposomes were developed that can penetrate through the BBB and deliver the reactivator of AChE pralidoxime chloride (2-PAM) into the brain. Liposomes were obtained on the basis of phosphatidylcholine and imidazolium surfactants. To obtain the composition optimized in terms of charge, stability, and toxicity, the molar ratio of surfactant/lipid was varied. For the systems, physicochemical parameters, release profiles of the substrates (rhodamine B, 2-PAM), hemolytic activity and ability to cause hemagglutination were evaluated. Screening of liposome penetration through the BBB, analysis of 2-PAM pharmacokinetics, and in vivo AChE reactivation showed that modified liposomes readily pass into the brain and reactivate brain AChE in rats poisoned with paraoxon (POX) by 25%. For the first time, an assessment was made of the ability of imidazolium liposomes loaded with 2-PAM to reduce the death of neurons in the brains of mice. It was shown that intravenous administration of liposomal 2-PAM can significantly reduce POX-induced neuronal death in the hippocampus.

Identifiants

pubmed: 36145698
pii: pharmaceutics14091950
doi: 10.3390/pharmaceutics14091950
pmc: PMC9506492
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Russian Science Foundation
ID : 19-73-30012

Références

Toxicology. 2020 Nov;444:152578
pubmed: 32898602
Eur J Pharm Sci. 2010 Aug 11;40(5):385-403
pubmed: 20497904
Int J Pharm. 2016 Dec 30;515(1-2):331-342
pubmed: 27769885
Mini Rev Med Chem. 2013 Dec;13(14):2102-15
pubmed: 24195661
Toxicol Lett. 2020 May 15;324:86-94
pubmed: 31954867
Life Sci. 2020 Jan 1;240:117099
pubmed: 31760098
Chemistry. 2016 Jul 25;22(31):10718-35
pubmed: 27276233
Curr Pharm Biotechnol. 2012 Sep;13(12):2310-8
pubmed: 23016637
Toxicol Sci. 2018 Apr 1;162(2):611-621
pubmed: 29272548
Clin Med Res. 2007 Mar;5(1):71-82
pubmed: 17456837
J Appl Toxicol. 2019 Nov;39(11):1506-1515
pubmed: 31264735
Mol Pharm. 2009 Sep-Oct;6(5):1363-70
pubmed: 19281192
Int J Mol Sci. 2020 Sep 22;21(18):
pubmed: 32971917
Colloids Surf B Biointerfaces. 2019 Jun 1;178:352-357
pubmed: 30901595
Bratisl Lek Listy. 2010;111(9):502-4
pubmed: 21180265
Pharmaceutics. 2021 Aug 17;13(8):
pubmed: 34452234
Chemosphere. 2003 Dec;53(9):1137-46
pubmed: 14512118
Pharmaceutics. 2022 Apr 02;14(4):
pubmed: 35456613
Nanoscale. 2016 May 5;8(18):9537-47
pubmed: 26730700
Biosens Bioelectron. 2019 Sep 1;140:111348
pubmed: 31153016
Int J Nanomedicine. 2019 Aug 14;14:6497-6517
pubmed: 31616141
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
J Control Release. 2008 Apr 21;127(2):97-109
pubmed: 18313785
Pharmaceutics. 2021 Jul 09;13(7):
pubmed: 34371738
J Control Release. 2018 Nov 28;290:102-111
pubmed: 30308259
J Control Release. 2018 Jan 28;270:290-303
pubmed: 29269142
Adv Colloid Interface Sci. 2016 May;231:36-58
pubmed: 27063924
Int J Pharm. 2005 Jul 25;298(2):274-92
pubmed: 15896933
Int J Pharm. 2020 Sep 25;587:119640
pubmed: 32673770
Pharmaceutics. 2022 May 05;14(5):
pubmed: 35631575
ACS Appl Mater Interfaces. 2017 May 24;9(20):16922-16932
pubmed: 28504886
Pharmaceutics. 2022 May 04;14(5):
pubmed: 35631573
J Pharm Sci. 2014 Jan;103(1):29-52
pubmed: 24338748
Clin Chim Acta. 2014 Apr 20;431:66-76
pubmed: 24508992
PLoS One. 2010 Dec 03;5(12):e14213
pubmed: 21151975
Int J Pharm. 2021 Aug 10;605:120803
pubmed: 34144135
Toxicology. 2019 Jul 1;423:75-83
pubmed: 31112674
J Drug Target. 2012 Jun;20(5):416-21
pubmed: 22519867
Neurotoxicology. 2016 Mar;53:64-73
pubmed: 26751814
ACS Omega. 2022 Jul 12;7(29):25741-25750
pubmed: 35910111
Pharmaceutics. 2022 Apr 11;14(4):
pubmed: 35456671
Biochem Pharmacol. 1961 Jul;7:88-95
pubmed: 13726518
Biochem J. 1953 Jan;53(1):62-7
pubmed: 13032034
Colloids Surf B Biointerfaces. 2018 Nov 1;171:358-367
pubmed: 30059851
Neurotoxicology. 2016 May;54:140-152
pubmed: 27108687
Gene Ther. 2002 Jul;9(13):850-8
pubmed: 12080379
Int J Mol Sci. 2022 Jan 18;23(3):
pubmed: 35162957
Chem Phys Lipids. 2019 Sep;223:104791
pubmed: 31326390
Prog Lipid Res. 2017 Oct;68:1-11
pubmed: 28778472
Pharmaceutics. 2022 May 26;14(6):
pubmed: 35745701
J Toxicol. 2020 Sep 22;2020:3007984
pubmed: 33029136
Pharmaceutics. 2022 Jun 16;14(6):
pubmed: 35745855
Molecules. 2021 Nov 10;26(22):
pubmed: 34833877
Ecotoxicol Environ Saf. 2021 Jan 1;207:111483
pubmed: 33120277
J Mater Chem B. 2019 Dec 14;7(46):7351-7362
pubmed: 31696196
Asian J Pharm Sci. 2019 Sep;14(5):480-496
pubmed: 32104476
Molecules. 2021 Apr 19;26(8):
pubmed: 33921656
J Control Release. 2017 Aug 28;260:61-77
pubmed: 28549949
Langmuir. 2022 Apr 26;38(16):4921-4934
pubmed: 35405069
Mater Sci Eng C Mater Biol Appl. 2016 Dec 1;69:1010-7
pubmed: 27612797
Biomed Mater. 2021 Feb 18;16(2):024104
pubmed: 33455956
Acta Pharm Sin B. 2016 Jul;6(4):268-86
pubmed: 27471668
Chem Biol Interact. 2021 Sep 1;346:109577
pubmed: 34274336
Anal Biochem. 2014 Oct 1;462:67-75
pubmed: 24929086
Chem Biol Interact. 2021 Aug 25;345:109558
pubmed: 34147486
Pharmaceutics. 2022 Jun 05;14(6):
pubmed: 35745775
ACS Omega. 2022 Jan 14;7(3):3073-3082
pubmed: 35097302
Brain Res. 2000 Aug 25;874(2):123-30
pubmed: 10960596
J Hazard Mater. 2022 Feb 15;424(Pt B):127494
pubmed: 34687999
J Neurooncol. 2014 Dec;120(3):489-97
pubmed: 25195130
Int J Pharm. 2019 Mar 25;559:360-372
pubmed: 30721725
Toxicol Sci. 2019 Jun 1;169(2):465-474
pubmed: 30835286
Toxicol Lett. 2009 Dec 15;191(2-3):297-304
pubmed: 19793545

Auteurs

Darya A Kuznetsova (DA)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Gulnara A Gaynanova (GA)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Elmira A Vasilieva (EA)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Rais V Pavlov (RV)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Irina V Zueva (IV)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Vasily M Babaev (VM)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Denis M Kuznetsov (DM)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Alexandra D Voloshina (AD)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Konstantin A Petrov (KA)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Lucia Y Zakharova (LY)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Oleg G Sinyashin (OG)

Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Arbuzov Str. 8, 420088 Kazan, Russia.

Classifications MeSH